FP523 : Role of intravitreal dexamethasone implant as the primary therapy in Diabetic Macular Edema

Dr.SWATI KUMARI, S21164

Purpose:To evaluate the long-term efficacy and safety of the intravitreal dexamethasone implant in the treatment of DME as initial therapy. Methods:Thirty patient with DME having CMT >296µm received intravitreal dexamethasone implant as the initial therapy. All were followed up at 1 week, 1month, 3 month, 6 months and at 1 year, when BCVA, IOP, S/L examination, IO and OCT was done and the finding were recorded and analysed. Results: Our study had 26 males and 4 females with a mean age of presentation of 58.62 years. The mean decrease in CMT following intravitreal dexamethasone was 167.62+6.15, 183+8.96, 147.25+25.64µm at the end of 3,6,12months respectively and the mean improvement in VA was 2.15+1.83 lines at 6 month and 1.18+1.94 lines at 12 months. Conclusion:Intravitreal dexamethasone as initial therapy is not much studied. Hence, this novel approach which is both safe and efficacious for treatment of DME as initial therapy can to be considered as primary therapy for DME.